adrenal gland neoplasms

Summary

Summary: Tumors or cancer of the ADRENAL GLANDS.

Top Publications

  1. doi Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD
    Christopher J Ricketts
    Cancer Research UK Renal Molecular Oncology Group, Department of Medical and Molecular Genetics, University of Birmingham, Institute of Biomedical Research, Birmingham, United Kingdom
    Hum Mutat 31:41-51. 2010
  2. pmc Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
    Yuejuan Qin
    Departments of Medicine, San Antonio, Texas, USA
    Nat Genet 42:229-33. 2010
  3. doi Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma
    Nelly Burnichon
    INSERM, UMR970, Paris Cardiovascular Research Center, F 75015 Paris, France
    Hum Mol Genet 20:3974-85. 2011
  4. ncbi Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations
    Hartmut P H Neumann
    Department of Nephrology and Hypertension, Albert Ludwigs University, Freiburg, Germany
    JAMA 292:943-51. 2004
  5. pmc Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature
    Lucia Martiniova
    Section on Medical Neuroendocrinology, Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development NIH, 10 Center Drive MSC 1109, Bethesda, MD 20892 1109, USA
    Clin Exp Metastasis 26:239-50. 2009
  6. ncbi Management of the clinically inapparent adrenal mass ("incidentaloma")
    Melvin M Grumbach
    University of California, San Francisco, San Francisco, California, USA
    Ann Intern Med 138:424-9. 2003
  7. ncbi Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features
    R Rossi
    Dipartimento di Endocrinologia, Universita di Napoli Federico II, Italy
    J Clin Endocrinol Metab 85:1440-8. 2000
  8. ncbi Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients
    Zoran Erlic
    Department of Nephrology, Section of Preventive Medicine, Albert Ludwigs University, Hugstetter Strasse 55, Freiburg, Germany
    Clin Cancer Res 15:6378-85. 2009
  9. ncbi The diagnosis and management of malignant phaeochromocytoma and paraganglioma
    Alexandra Chrisoulidou
    Department of Endocrinology and Endocrine Oncology, Theagenion Hospital, Thessaloniki, Greece
    Endocr Relat Cancer 14:569-85. 2007
  10. ncbi State-of-the-art adrenal imaging
    W W Mayo-Smith
    Department of Radiology of Brown University, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903, USA
    Radiographics 21:995-1012. 2001

Detail Information

Publications260 found, 100 shown here

  1. doi Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD
    Christopher J Ricketts
    Cancer Research UK Renal Molecular Oncology Group, Department of Medical and Molecular Genetics, University of Birmingham, Institute of Biomedical Research, Birmingham, United Kingdom
    Hum Mutat 31:41-51. 2010
    ..The differing effect of the SDHD p.Pro81Leu on HNPGL and pheochromocytoma risks suggests differing mechanisms of tumorigenesis in SDH-associated HNPGL and pheochromocytoma...
  2. pmc Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
    Yuejuan Qin
    Departments of Medicine, San Antonio, Texas, USA
    Nat Genet 42:229-33. 2010
    ..Our studies identify TMEM127 as a tumor suppressor gene and validate the power of hereditary tumors to elucidate cancer pathogenesis...
  3. doi Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma
    Nelly Burnichon
    INSERM, UMR970, Paris Cardiovascular Research Center, F 75015 Paris, France
    Hum Mol Genet 20:3974-85. 2011
    ..Altogether, these new findings suggest that somatic mutation analysis is likely to yield important clues for personalizing molecular targeted therapies...
  4. ncbi Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations
    Hartmut P H Neumann
    Department of Nephrology and Hypertension, Albert Ludwigs University, Freiburg, Germany
    JAMA 292:943-51. 2004
    ..In both syndromes, pheochromocytomas as well as head and neck paragangliomas occur; however, details for individual risks and other clinical characteristics are unknown...
  5. pmc Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature
    Lucia Martiniova
    Section on Medical Neuroendocrinology, Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development NIH, 10 Center Drive MSC 1109, Bethesda, MD 20892 1109, USA
    Clin Exp Metastasis 26:239-50. 2009
    ..Microarray gene expression comparison and quantitative real-time PCR of these more aggressive cells to the MPC-parental cell line identified genes that may be important for the metastatic process...
  6. ncbi Management of the clinically inapparent adrenal mass ("incidentaloma")
    Melvin M Grumbach
    University of California, San Francisco, San Francisco, California, USA
    Ann Intern Med 138:424-9. 2003
    ..The panel also advocated a multidisciplinary approach to managing adrenal incidentalomas. The statement is an independent report of the panel and is not a policy statement of the National Institutes of Health or the federal government...
  7. ncbi Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features
    R Rossi
    Dipartimento di Endocrinologia, Universita di Napoli Federico II, Italy
    J Clin Endocrinol Metab 85:1440-8. 2000
    ..These findings support the hypothesis that clinically silent hypercortisolism is probably not completely asymptomatic...
  8. ncbi Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients
    Zoran Erlic
    Department of Nephrology, Section of Preventive Medicine, Albert Ludwigs University, Hugstetter Strasse 55, Freiburg, Germany
    Clin Cancer Res 15:6378-85. 2009
    ..The aim of the study is to systematically obtain a robust algorithm to identify who should be genetically tested, and to determine the order in which genes should be tested...
  9. ncbi The diagnosis and management of malignant phaeochromocytoma and paraganglioma
    Alexandra Chrisoulidou
    Department of Endocrinology and Endocrine Oncology, Theagenion Hospital, Thessaloniki, Greece
    Endocr Relat Cancer 14:569-85. 2007
    ..Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents...
  10. ncbi State-of-the-art adrenal imaging
    W W Mayo-Smith
    Department of Radiology of Brown University, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903, USA
    Radiographics 21:995-1012. 2001
    ..Certain features can be used by the radiologist to establish a definitive diagnosis for most adrenal masses (including carcinoma, infections, and hemorrhage) based on imaging findings alone...
  11. doi Laparoscopic adrenalectomy for adrenal tumors in children: a case series
    Pablo Laje
    Department of Pediatric Surgery, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Laparoendosc Adv Surg Tech A 19:S27-9. 2009
    ..The aims of this study were to present our experience with children who underwent laparoscopic adrenalectomy for adrenal tumors over a 4-year period, discuss the technical aspects of the procedure, and review the current literature...
  12. doi MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas
    Zsófia Tömböl
    Faculty of Medicine, 2nd Department of Medicine, Semmelweis University, Budapest, Hungary
    Mod Pathol 23:1583-95. 2010
    ..MicroRNA expression patterns differ between various sporadic, hereditary and recurring tumors and miR-1225-3p may be useful for identifying recurring pheochromocytomas...
  13. ncbi Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2
    Andreas Machens
    Department of General, Visceral, and Vascular Surgery, Martin Luther University Halle Wittenberg, Ernst Grube Strasse 40, D 06097 Halle Saale, Germany
    J Clin Endocrinol Metab 90:3999-4003. 2005
    ..Recent data suggest a codon-specific, age-related development of multiple endocrine neoplasia type 2...
  14. ncbi Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study
    Antonio Toniato
    Surgical Pathology Clinic, Department of Medical and Surgical Sciences, University of Padua School of Medicine, Padova, Italy
    Ann Surg 249:388-91. 2009
    ....
  15. doi Wnt/β-catenin signalling in adrenal physiology and tumour development
    Annabel Berthon
    CNRS UMR6247, Génétique Reproduction et Développement, Clermont Universite, Aubiere, France
    Mol Cell Endocrinol 351:87-95. 2012
    ..This review will summarise all these recent findings and will focus on some of the mechanisms that may lead to aberrant accumulation of β-catenin in adrenocortical tumours...
  16. doi Array-comparative genomic hybridization in sporadic benign pheochromocytomas
    Francien H van Nederveen
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 16:505-13. 2009
    ..In addition, genes on 21q and 22q might play a more important role in PCC pathogenesis than had been assumed thus far...
  17. ncbi Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay
    Michael A Blake
    Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, White 270, 55 Fruit St, Boston, MA 02114, USA
    Radiology 238:578-85. 2006
    ....
  18. ncbi Adrenal incidentaloma: a new cause of the metabolic syndrome?
    Massimo Terzolo
    Dipartimento di Scienze Cliniche e Biologiche, Medicina Interna I, Clinica Medica, A S O San Luigi, 10043 Orbassano, Italy
    J Clin Endocrinol Metab 87:998-1003. 2002
    ..Midnight serum cortisol appears as a sensitive marker of the metabolic effects of subclinical Cushing's syndrome...
  19. ncbi Adrenal masses: characterization with combined unenhanced and delayed enhanced CT
    Elaine M Caoili
    Department of Radiology, University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109 9723, USA
    Radiology 222:629-33. 2002
    ..To assess the accuracy of a dedicated adrenal computed tomographic (CT) protocol...
  20. ncbi A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines
    Anna M Sawka
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 88:553-8. 2003
    ....
  21. ncbi Pheochromocytoma: current approaches and future directions
    Joel T Adler
    Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin, USA
    Oncologist 13:779-93. 2008
    ..In this review, we discuss the presentation, diagnosis, management, and future directions in the management of this disease...
  22. pmc Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI
    Lucia Martiniova
    Reproductive and Adult Endocrinology Program, National Institutes of Child Health and Human Development, Bethesda, Maryland 20892 1109, USA
    J Magn Reson Imaging 29:685-91. 2009
    ..However, the choice of imaging modality is still evolving...
  23. ncbi Extra-adrenal pheochromocytoma: diagnosis and management
    Grant I S Disick
    Department of Urology, The Mount Sinai Medical Center, One Gustave L Levy Place, Box 1272, New York, NY 10029, USA
    Curr Urol Rep 8:83-8. 2007
    ..Recent reports suggest that a laparoscopic approach, along with intraoperative ultrasound, can safely remove these tumors. EAPs recur and metastasize more often than their adrenal counterparts, making lifelong follow-up essential...
  24. ncbi Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas
    Anne Paule Gimenez-Roqueplo
    AP HP, Hopital Europeen Georges Pompidou, Département de Génétique Moléculaire, Paris
    Cancer Res 63:5615-21. 2003
    ..These data strongly suggest that SDHB gene is a tumor suppressor gene and that the identification of germ-line mutations in SDHB gene in patients with ASPs should be considered as a high-risk factor for malignancy or recurrence...
  25. ncbi Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis
    Tawee Tanvetyanon
    Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
    J Clin Oncol 26:1142-7. 2008
    ..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis...
  26. pmc Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma
    Henri J L M Timmers
    Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 94:4757-67. 2009
    ....
  27. ncbi Imaging of neuroendocrine tumors
    Vittoria Rufini
    Department of Nuclear Medicine, Universita Cattolica del Sacro Cuore, Rome, Italy
    Semin Nucl Med 36:228-47. 2006
    ..New somatostatin analogs with different receptor affinity as well as other peptides are currently under investigation and will further improve our diagnostic and therapeutic capabilities in the future...
  28. pmc Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy
    Lucia Martiniova
    Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e14678. 2011
    ..Subsequently, we evaluated the increased efficacy of chemotherapy combined with LB1...
  29. doi Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma
    Judith Favier
    INSERM, UMR970, Paris Cardiovascular Research Center, Paris, France
    Endocr Pathol 23:34-42. 2012
    ..Our results suggest that there is a strong rationale for anti-VEGF-based therapeutic strategies in malignant pheochromocytomas and paragangliomas, in particular in those associated with mutations in the SDHB gene...
  30. ncbi Pheochromocytoma: state-of-the-art and future prospects
    Emmanuel L Bravo
    Department of Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland Ohio 44195, USA
    Endocr Rev 24:539-53. 2003
    ....
  31. pmc Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma
    Graeme Eisenhofer
    Institute of Clinical Chemistry and Laboratory Medicine, University of Dresden, Dresden, Germany
    Am J Physiol Endocrinol Metab 295:E1223-33. 2008
    ....
  32. doi Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma
    Esther Korpershoek
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Pathol 217:597-604. 2009
    ..The mouse model should allow further studies into the pathogenesis of human malignant PCCs and into therapeutic strategies for these tumours...
  33. ncbi Endoscopic adrenalectomy: an analysis of the transperitoneal and retroperitoneal approaches and results of a prospective follow-up study
    I Gockel
    Department of General and Abdominal Surgery, Johannes Gutenberg University, Langenbeckstrasse 1, 55101 Mainz, Germany
    Surg Endosc 19:569-73. 2005
    ..The aim of this study was to determine which of these is the optimal surgical technique in a prospectively designed analysis of a large series of patients operated on by a single team over a 10-year period...
  34. pmc Adrenal schwannoma treated with laparoscopic surgery
    Naoyoshi Onoda
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
    JSLS 12:420-5. 2008
    ..We report a case of left adrenal schwannoma in a 62-year-old man, incidentally discovered on an abdominal computed tomography. It was successfully treated with laparoscopic adrenalectomy...
  35. ncbi The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A
    Klaus Martin Schulte
    Department of Endocrine Surgery, King s College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    J Clin Endocrinol Metab 95:E92-7. 2010
    ..A strong genotype-phenotype correlation results in major implications for the clinical approach. More information on less common mutations is needed to advance specific guidance...
  36. ncbi Changing paradigms in the treatment of malignant pheochromocytoma
    Raymon H Grogan
    Department of Endocrine Surgery, University of California, San Francisco, CA 94143, USA
    Cancer Control 18:104-12. 2011
    ..Recently, however, the genetic and molecular changes involved in malignant pheochromocytoma have come to be understood...
  37. doi Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience
    Franco Casamassima
    Clinical Radiobiological Institute, University of Florence, Florence, Italy
    Int J Radiat Oncol Biol Phys 82:919-23. 2012
    ..To evaluate a retrospective single-institution outcome after hypofractionated stereotactic body radiotherapy (SBRT) for adrenal metastases...
  38. doi Genetics of pheochromocytoma and paraganglioma in Spanish patients
    Alberto Cascon
    Hereditary Endocrine Cancer Group, Institute de Salud Carlos III Center for Biomedical Research on Rare Diseases, Madrid, Spain
    J Clin Endocrinol Metab 94:1701-5. 2009
    ..In these cases, other clinical aspects like bilaterality, multiplicity, location of the tumors, or age at onset can help to recognize the underlying genes involved...
  39. doi Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer
    Yoshiko Oshiro
    Department of Radiation Oncology, International Medical Center of Japan, Tokyo, Japan
    Am J Clin Oncol 34:249-53. 2011
    ..In this study, we evaluated the clinical results of radiotherapy performed for local control in patients with this disease...
  40. doi 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation
    Catherine Ansquer
    Service de Medecine Nucleaire, CHU Hotel Dieu, Nantes, France
    Eur J Nucl Med Mol Imaging 37:1669-78. 2010
    ..This prospective multicentre study assesses the usefulness of FDG PET/CT in characterizing and making the therapeutic decision concerning adrenal tumours that are suspicious or indeterminate in nature after conventional examinations (CE)...
  41. ncbi Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma
    Hiroka Takahashi
    Department of Pediatrics, St Luke s International Hospital, Chuo Ku, Tokyo, Japan
    Pediatr Blood Cancer 50:676-8. 2008
    ..Neither acute nor chronic graft-versus-host disease (GVHD) was observed. The patient remained in remission for 3 months after RIST until the second relapse. MIBG therapy combined with RIST warrants further trials...
  42. ncbi Uncommon adrenal masses: CT and MRI features with histopathologic correlation
    Ying Kun Guo
    Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
    Eur J Radiol 62:359-70. 2007
    ..Moreover, CT and MRI are highly accurate in localization of uncommon adrenal masses, and useful to guide surgical treatments...
  43. ncbi Non-invasive evaluation of the incidentally detected indeterminate adrenal mass
    Mahmoud M Al-Hawary
    Department of Radiology, University of Michigan Hospitals, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0030, USA
    Best Pract Res Clin Endocrinol Metab 19:277-92. 2005
    ..e. the differentiation of benign from malignant masses). The imaging techniques and the algorithms that are used in our institution for the evaluation of incidentally detected adrenal mass will be described...
  44. ncbi ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice
    Edwin W Lai
    Lombardi Cancer Comprehensive Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA
    Cell Cycle 6:1946-50. 2007
    ..These data establish that increased ErbB-2 growth factor receptor signaling in the adrenal medulla can lead to PCC through combined influences on Pten, AKT andcyclin D1...
  45. doi Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study
    Guido Di Dalmazi
    Endocrinology Unit, Department of Clinical Medicine, S Orsola Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, Bologna, Italy
    Eur J Endocrinol 166:669-77. 2012
    ..Whether SCS leads to metabolic and cardiovascular diseases is still controversial...
  46. ncbi Schwannoma of the adrenal gland: report of two cases
    Sean K Lau
    Department of Pathology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Am J Surg Pathol 30:630-4. 2006
    ..Because of its rarity, schwannoma occurring at this particular site can pose problems in diagnosis and should be distinguished from other spindle cell lesions of the adrenal gland...
  47. ncbi Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects
    V Morelli
    Unit of Endocrinology and Diabetology, Department of Medical Sciences, Universita degli Studi di Milano, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan
    Clin Endocrinol (Oxf) 73:161-6. 2010
    ..We aimed to investigate the accuracy of different SH diagnostic criteria in predicting the presence of complications...
  48. doi Should we use laparoscopic adrenalectomy for metastases? Scandinavian multicenter study
    Irina Pavlik Marangos
    Interventional Centre, Rikshospitalet University Hospital, Oslo, Norway
    J Surg Oncol 100:43-7. 2009
    ..Laparoscopic adrenalectomy for metastases is considered controversial. Multicenter retrospective study was performed to gain new knowledge in this issue...
  49. doi Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)
    M R Druce
    Department of Endocrinology, Barts and the London School of Medicine, London, UK
    Horm Metab Res 41:697-702. 2009
    ..We outline these four cases and review the theoretical background for this therapy, although the outcomes were relatively disappointing...
  50. doi Adrenal ganglioneuromas: incidentalomas with misleading clinical and imaging features
    Dimitrios Linos
    1st Surgical Clinic, Diagnostic and Therapeutic Center of Athens Hygeia, Athens, Greece
    Surgery 149:99-105. 2011
    ..Ganglioneuromas are benign neoplasms of the neural crest, occurring rarely in the adrenal glands. This study presents our experience regarding diagnostic and therapeutic management of these neoplasms and a review of the relevant literature...
  51. ncbi Schwannomas of the left adrenal gland and posterior mediastinum
    Chwen Yi Yang
    Division of Endocrinology and Metabolism, Department of Medicine, Chi Mei Hospital, Tainan, Taiwan, ROC
    J Chin Med Assoc 72:83-7. 2009
    ..Total excision of benign schwannoma is associated with favourable outcome in patients...
  52. ncbi Synchronous presentation of primary non-small cell lung carcinoma and pheochromocytoma
    Edward P Chen
    Division of Cardiothoracic Surgery and General Surgery, Emory University Affiliated Hospitals, Atlanta, Georgia, USA
    Ann Thorac Surg 74:924-6. 2002
    ..This case illustrates the importance of establishing a firm diagnosis for all synchronously present adrenal lesions that are discovered in the setting of primary lung carcinoma...
  53. ncbi Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma
    Goswin Y Meyer-Rochow
    Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, Australia
    J Surg Res 157:55-62. 2009
    ..The aim of this study was to evaluate denaturing high performance liquid chromatography (dHPLC) as a screening tool for the detection of germline mutations within VHL, SDHB, and SDHD in pheochromocytoma patients...
  54. doi Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas M D Anderson Cancer, Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:386-91. 2009
    ..von Hippel-Lindau disease is characterized by highly vascularized tumors of multiple organs...
  55. pmc Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma
    Sara Molatore
    Department of Pathology, Helmholtz Zentrum Munchen, 85764 Neuherberg, Germany
    Proc Natl Acad Sci U S A 107:18493-8. 2010
    ..These studies reveal clues to the molecular pathways involved in rat and human pheochromocytoma and identify previously unexplored biomarkers for clinical use...
  56. doi Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies
    Svenja Nölting
    Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Endocr Pathol 23:21-33. 2012
    ....
  57. pmc Adrenal schwannoma
    Eugen Tarcoveanu
    First Surgical Clinic, St Spiridon Hospital, University of Medicine, Iaçsi, Romania
    JSLS 13:116-9. 2009
    ..We report the case of a left adrenal schwannoma incidentally discovered in a 55-year-old man during a postoperative checkup for a cutaneous malignant melanoma...
  58. pmc Hereditary paraganglioma targets diverse paraganglia
    B E Baysal
    Department of Psychiatry, The University of Pittsburgh Medical Center, 3811 O Hara Street R1445, Pittsburgh, PA, 15213, USA
    J Med Genet 39:617-22. 2002
    ..This short review attempts to bring together relevant genetic data on paragangliomas with a particular emphasis on head and neck paragangliomas and phaeochromocytomas...
  59. doi Phaeochromocytomas and sympathetic paragangliomas
    B J Petri
    Department of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
    Br J Surg 96:1381-92. 2009
    ..Surgical resection is the treatment of choice for both PCC and sPGL, but controversy exists about the management of patients with bilateral or multiple tumours...
  60. doi Single access retroperitoneoscopic adrenalectomy (SARA)--one step beyond in endocrine surgery
    Martin K Walz
    Klinik für Chirurgie und Zentrum für Minimal Invasive Chirurgie, Kliniken Essen Mitte, Akademisches Lehrkrankenhaus der Universität Duisburg Essen, Henricistrasse 92, 45136, Essen, Germany
    Langenbecks Arch Surg 394:447-50. 2009
    ..Today, endoscopic adrenalectomy has become a gold standard in endocrine surgery...
  61. ncbi Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors
    Peter M Sadow
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Endocr Pathol 19:97-103. 2008
    ..These results show that stathmin is expressed at higher levels in more rapidly proliferating endocrine tumors. However, it is probably not useful as a stand-alone marker to determine malignancy in pheochromocytomas for individual tumors...
  62. doi Stathmin as a marker for malignancy in pheochromocytomas
    P Bjorklund
    Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Exp Clin Endocrinol Diabetes 118:27-30. 2010
    ..The results introduce stathmin as a possible diagnostic marker for malignant pheochromocytomas, and further evaluations are warranted...
  63. ncbi Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients
    Martin K Walz
    Klinik für Chirurgie und Zentrum für Minimal Invasive Chirurgie, Kliniken Essen Mitte, Akademisches Lehrkrankenhaus der Universität Duisburg Essen, Henricistrasse 92, Essen, D 45136, Germany
    World J Surg 30:899-908. 2006
    ....
  64. ncbi Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma
    Carsten Boltze
    Department of Pathology, Otto von Guericke University, D 39120 Magdeburg, Germany
    J Clin Endocrinol Metab 88:4280-6. 2003
    ..The common expression of hTERT and telomerase activity thus represents an additional prognostic marker that may identify more aggressive tumors...
  65. ncbi Laparoscopic management of adrenal lesions larger than 5 cm in diameter
    Rajan Sharma
    Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India
    Urol J 6:254-9. 2009
    ..The incidence of adrenocortical carcinoma increases and technical difficulty of adrenalectomy increases as the size increases. We examined the outcome and complications of laparoscopic adrenalectomy for such lesions...
  66. doi Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study
    S Schaefer
    Division of Endocrinology and Diabetology, Philipp s University, D 35033 Marburg, Germany EU
    Eur J Endocrinol 158:699-704. 2008
    ....
  67. doi Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program
    James Lee
    Division of Gastrointestinal and Endocrine Surgery, Columbia University, New York, NY, USA
    J Am Coll Surg 206:953-9; discussion 959-61. 2008
    ..This study uses the Veterans Affairs National Surgical Quality Improvement Program database to compare these two approaches, adjusting for baseline differences...
  68. ncbi Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening
    J Waldmann
    Department of General Surgery, Philipps University, Marburg, Germany
    Langenbecks Arch Surg 392:437-43. 2007
    ..Prevalence in recent studies varies between 9 and 45%. A genotype-phenotype correlation has been described as well as the development of adrenocortical carcinomas. Long-term prospective data are still lacking...
  69. ncbi Pheochromocytoma and extra-adrenal paraganglioma: updates
    Arthur S Tischler
    Department of Pathology, Tufts New England Medical Center, Boston, MA 02111, USA
    Arch Pathol Lab Med 132:1272-84. 2008
    ..These developments are concurrent with the publication and dissemination of the 2004 World Health Organization bluebook on pathology and genetics of endocrine tumors...
  70. ncbi Retroperitoneoscopic adrenalectomy for adrenal tumors via a single large port
    Daisaku Hirano
    Department of Urology, Nihon University School of Medicine, Tokyo, Japan
    J Endourol 19:788-92. 2005
    ..This study reports the outcomes of retroperitoneoscopic adrenalectomy (RA) for adrenal tumors via a single port using a large cylinder without carbon dioxide insufflation...
  71. ncbi Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma
    K Pacak
    Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 9D42, 10 Center Drive MSC 1583, Bethesda, MD 20892 1583, USA
    Ann Intern Med 134:315-29. 2001
    ....
  72. ncbi Cardiogenic shock due to acute hemorrhagic necrosis of a pheochromocytoma: a case report and review of the literature
    Hassan A Mohamed
    Department of Medicine, Regina General Hospital, Regina, Saskatchewan
    Can J Cardiol 19:573-6. 2003
    ..This case illustrates an unusual presentation of pheochromocytoma and emphasizes the importance of aggressive and appropriate medical therapy in pheochromocytoma heart disease...
  73. ncbi Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results
    Graeme Eisenhofer
    Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 88:2656-66. 2003
    ..Patterns of biochemical test results and responses of plasma normetanephrine to clonidine can then help distinguish true- from false-positive results...
  74. ncbi Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma
    O Gimm
    Department of Internal Medicine, The Ohio State University, Columbus 43210, USA
    Cancer Res 60:6822-5. 2000
    ....
  75. ncbi Perioperative management of pheochromocytoma
    Michelle A O Kinney
    Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA
    J Cardiothorac Vasc Anesth 16:359-69. 2002
  76. ncbi Biochemical diagnosis of pheochromocytoma: which test is best?
    Jacques W M Lenders
    Department of Internal Medicine, St Radboud University Medical Center, Geert Grooteplein Zuid 8, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    JAMA 287:1427-34. 2002
    ..Diagnosis of pheochromocytoma depends on biochemical evidence of catecholamine production by the tumor. However, the best test to establish the diagnosis has not been determined...
  77. ncbi Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma
    Laurence Amar
    Hypertension Unit, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    J Clin Endocrinol Metab 90:2110-6. 2005
    ..In conclusion, pheochromocytomas/paragangliomas can now be diagnosed earlier, with smaller tumors, and more frequently as incidentalomas. Familial, right adrenal, and extraadrenal tumors recur more frequently than left adrenal tumors...
  78. ncbi Adrenal involvement in multiple endocrine neoplasia type 1
    Peter Langer
    Department of Surgery, Philipps University Hospital, Baldingerstrasse, D 35043 Marburg, Germany
    World J Surg 26:891-6. 2002
    ..The lesions are often small and nonfunctional and can therefore be managed by close surveillance; others have significant malignant potential and should be considered for surgery when they are 3 cm or larger...
  79. ncbi Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    ..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors...
  80. ncbi High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing
    Frederieke M Brouwers
    Section of Medical Neuroendocrinology, Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institute of Health, Bethesda, Maryland 20892 1109, USA
    J Clin Endocrinol Metab 91:4505-9. 2006
    ..Mutations of the gene for succinate dehydrogenase subunit B (SDHB) are associated with a high risk of malignancy, but establishing the precise contribution requires relatively large numbers of patients with well-defined malignancy...
  81. doi Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients
    Hui Huang
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 113:2020-8. 2008
    ..A long-term follow-up was conducted of 18 patients with a diagnosis of pheochromocytoma/paraganglioma treated with a combination of cyclophosphamide, vincristine, and dacarbazine (CVD)...
  82. doi Clinical and molecular progress in hereditary paraganglioma
    B E Baysal
    Department of Pathology, Yale University School of Medicine, 310 Cedar Street, BML B38, New Haven, CT 06520 8023, USA
    J Med Genet 45:689-94. 2008
    ....
  83. ncbi Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice
    J F Powers
    Department of Pathology, Box 802, New England Medical Center and Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Cell Tissue Res 302:309-20. 2000
    ..Mouse pheochromocytomas are a new tool for studying genes and signaling pathways that regulate cell growth and differentiation in adrenal medullary neoplasms and are a unique model for studying the regulation of PNMT expression...
  84. ncbi Primary adrenal lymphoma
    Andrew P Grigg
    Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Clin Lymphoma 4:154-60. 2003
    ..Multicenter collaborative retrospective reviews and prospective trials are needed to address these issues...
  85. doi Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma
    Robert Kopetschke
    Clinical Endocrinology, Charite Campus Mitte, Charite University Medicine Berlin, Chariteplatz 1, D 10117 Berlin, Germany
    Eur J Endocrinol 161:355-61. 2009
    ..However, an increasing proportion of phaeochromocytoma seems to be discovered incidentally upon abdominal imaging...
  86. pmc A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy
    Kyung Min Kim
    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Korean Med Sci 24:525-8. 2009
    ..To our knowledge, this is the second report to date of a patient with primary bilateral adrenal diffuse large B-cell lymphoma who achieved complete remission using R-CHOP chemotherapy...
  87. doi Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report
    E L Bravo
    Glickman Urological and Kidney Institute, Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH 44195, USA
    Horm Metab Res 41:703-6. 2009
    ..However, the present findings need confirmation in a larger study and the role of temozolomide in the long-term treatment of malignant paraganglioma/pheochromocytoma remains to be established...
  88. ncbi Phaeochromocytoma crisis--a rare indication for extracorporeal membrane oxygenation
    A Chao
    Department of Anaesthesia and Intensive Care, National Taiwan University Hospital, 7, Chung Shan S Road, Taipei, 100, Taiwan
    Anaesthesia 63:86-8. 2008
    ....
  89. ncbi Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis
    Ana Mozos
    Department of Anatomic Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Mod Pathol 22:1210-7. 2009
    ..We speculate that the poor outcome of primary adrenal lymphoma might be related to the bulky tumor size at presentation, non-germinal center B-cell phenotype, and frequent BCL-6 gene rearrangement...
  90. pmc Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas
    Li Yao
    Division of Hematology and Molecular Oncology, Department of Medicine and Cellular, Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, MC7880, San Antonio, Texas 78229, USA
    J Clin Endocrinol Metab 95:1469-72. 2010
    ..Mutations in genes involved in the energy metabolism, isocitrate dehydrogenase 1 (IDH1) and -2 (IDH2) and SDHAF2, a component of SDH, can mimic a pseudohypoxic state...
  91. ncbi Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes
    Anthony J Gill
    Department of Anatomical Pathology, Royal North Shore Hospital, Sydney 2065, Australia
    Hum Pathol 41:805-14. 2010
    ..Completely absent staining is more commonly found with SDHB mutation, whereas weak diffuse staining often occurs with SDHD mutation...
  92. doi Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients
    Jean Pierre Bayley
    Department of Human Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Endocr Relat Cancer 16:929-37. 2009
    ..Gene deletions of SDHD and SDHC represent a substantial proportion of all mutations, and must be considered in paraganglioma patients shown to be negative for mutations by sequencing...
  93. ncbi Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy
    Kaoru Nomura
    Department of General Medicine, Tokyo Women s Medical University, 8 1 Kawadacho, Shinjyuku ku, Tokyo, Japan
    J Clin Endocrinol Metab 94:2850-6. 2009
    ..About 10% of pheochromocytomas are malignant. Exact survival has not been reported, nor has an analysis of the efficacy of chemotherapy on survival time...
  94. doi Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma
    Kyung Sun Park
    Department of Oncology and Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Songpa Gu, Seoul, Republic of Korea
    Jpn J Clin Oncol 39:327-31. 2009
    ..The tumor showed very good metabolic response to the therapy. In patient with malignant pheochromocytoma, sunitinib might be one therapeutic strategy for malignant pheochromocytomas...
  95. doi Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas
    Massimo Mannelli
    Department Clinical Pathophysiology, University of Florence, Viale Pieraccini 5, 50139 Florence, Italy
    J Clin Endocrinol Metab 94:1541-7. 2009
    ..The aim of the study was to define the frequency of hereditary forms and the genotype/phenotype correlations in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas...
  96. pmc A rare coexistence of adrenal cavernous hemangioma with extramedullar hemopoietic tissue: a case report and brief review of the literature
    Nikolaos Arkadopoulos
    2nd Department of Surgery, Aretaieion Hospital, Athens University School of Medicine, Athens, Greece
    World J Surg Oncol 7:13. 2009
    ..Cavernous hemangiomas of the adrenal gland are rare, benign, non-functioning neoplastic tumors. To our knowledge, 55 cases have been reported in the literature to date...
  97. ncbi Abnormalities in incidentally removed adrenal glands
    H Buurman
    Institute of Pathology of the Marienkrankenhaus Hamburg, Hamburg, Germany
    Endocr Pathol 17:277-82. 2006
    ..1%) did not exhibit any pathological findings. The adrenals exhibited infiltration or metastasis by malignant tumors (6.4%), adrenal adenomas (2.5%), adrenal hyperplasias (31.6%), and other alterations (38.7%)...
  98. ncbi Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model
    Tania L Mazzuco
    Institut National de la Sante et de la Recherche Medicale, Equipe Mixte 105, DRDC, CEA, Grenoble, France
    Endocrinology 147:782-90. 2006
    ..Thus, a single genetic event, inappropriate expression of a nonmutated GPCR gene, is sufficient to initiate the complete phenotypic alterations that ultimately lead to the formation of a benign adrenocortical tumor...
  99. ncbi The transcriptional regulating protein of 132 kDa (TReP-132) enhances P450scc gene transcription through interaction with steroidogenic factor-1 in human adrenal cells
    Florence Gizard
    Oncology and Molecular Endocrinology Research Center, Laval University, Quebec GIK 7P4, Canada
    J Biol Chem 277:39144-55. 2002
    ..Taken together the results in this study identify a novel function of TReP-132 as a partner in a complex with SF-1 and CBP/p300 to regulate gene transcription involved in steroidogenesis...
  100. ncbi Laparoscopic adrenalectomy for pheochromocytoma
    W Keat Cheah
    Department of Surgery, University of California San Francisco, Veterans Affairs Medical Center, 4150 Clement Street, 94121, USA
    World J Surg 26:1048-51. 2002
    ..Laparoscopic adrenalectomy is the preferred surgical approach for patients with pheochromocytoma because it is safe and efficacious...
  101. ncbi Spontaneous rupture of adrenal pheochromocytoma: review and analysis of prognostic factors
    Takashi Kobayashi
    Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan
    J Surg Oncol 90:31-5. 2005
    ..Because of its rarity, the clinical characteristics of the manifestation of a ruptured pheochromocytoma and factors influencing on treatment outcomes in patients are still unclear...

Research Grants85

  1. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    HECTOR MOBINE; Fiscal Year: 2007
    ..The findings may not only afford further appreciation of the pathophysiology and etiology of peripartum cardiomyopathy but also of general mechanisms in disease progression. [unreadable] [unreadable] [unreadable]..
  2. SECURIN REGULATION OF PANCREATIC beta CELL MASS
    Run Yu; Fiscal Year: 2007
    ..John Adams and Basil Rapoport). Building on my extensive basic and clinical training, I expect to become an independent endocrine researcher upon completion of this K08 grant . ..
  3. SECURIN REGULATION OF PANCREATIC beta CELL MASS
    Run Yu; Fiscal Year: 2008
    ..John Adams and Basil Rapoport). Building on my extensive basic and clinical training, I expect to become an independent endocrine researcher upon completion of this K08 grant . ..
  4. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2002
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  5. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2002
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  6. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2000
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  7. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2006
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  8. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2001
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  9. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2005
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  10. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 1999
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  11. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2003
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  12. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2003
    ..4) To determine the status of neurofibromin in MPC cells and test the hypothesis that abnormal regulation of ras activity is responsible for neuronal differentiation in this model. ..
  13. CHROMAFFIN CELL PROLIFERATION IN NEOPLASTIC PROGRESSION
    Arthur Tischler; Fiscal Year: 2004
    ..The proposed studies will help to elucidate mechanisms that may be involved in the development and progression of pheochromocytomas. ..
  14. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2005
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  15. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2006
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  16. TRAINING PROGRAM IN CLINICAL RESEARCH
    David Schteingart; Fiscal Year: 2004
    ..abstract_text> ..
  17. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2004
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  18. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2003
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  19. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2007
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  20. Mechanisms of Cholinesterase Inhibitors on Beta-amyloid
    Debomoy Lahiri; Fiscal Year: 2006
    ..This property will be further investigated to maximize their potential effects in decreasing amyloid depositions, and which can be utilized to design better drugs for the treatment of AD. ..
  21. Regulation of APP Pathway Gene Promoters in Alzheimer's
    Debomoy Lahiri; Fiscal Year: 2007
    ..Studying APP and BACE gene regulation is crucial to understand APP production leading to Aa generation. These studies should help developing suitable drug targets for the treatment of Alzheimer's disease. ..
  22. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    HECTOR MOBINE; Fiscal Year: 2008
    ..The findings may not only afford further appreciation of the pathophysiology and etiology of peripartum cardiomyopathy but also of general mechanisms in disease progression. [unreadable] [unreadable] [unreadable]..
  23. Cholinesterase Inhibitors in Alzheimer's Disease
    Debomoy Lahiri; Fiscal Year: 2008
    ..The outcome of the proposal is to identify mechanisms by which ChEIs block potentially toxic AB levels and to utilize this property in developing novel therapeutic agents. ..
  24. Regulation of APP Pathway Gene Promoters in Alzheimer's
    Debomoy Lahiri; Fiscal Year: 2008
    ..Studying APP and BACE gene regulation is crucial to understand APP production leading to Aa generation. These studies should help developing suitable drug targets for the treatment of Alzheimer's disease. ..
  25. Cholinesterase Inhibitors in Alzheimer's Disease
    Debomoy Lahiri; Fiscal Year: 2009
    ..The outcome of the proposal is to identify mechanisms by which ChEIs block potentially toxic AB levels and to utilize this property in developing novel therapeutic agents. ..
  26. Regulation of APP Pathway Gene Promoters in Alzheimer's
    Debomoy Lahiri; Fiscal Year: 2009
    ..Studying APP and BACE gene regulation is crucial to understand APP production leading to Aa generation. These studies should help developing suitable drug targets for the treatment of Alzheimer's disease. ..
  27. Mechanisms of Cholinesterase Inhibitors on Beta-amyloid
    Debomoy Lahiri; Fiscal Year: 2004
    ..This property will be further investigated to maximize their potential effects in decreasing amyloid depositions, and which can be utilized to design better drugs for the treatment of AD. ..
  28. APP GENE PROMOTER IN ALZHEIMER'S DISEASE
    Debomoy Lahiri; Fiscal Year: 2001
    ..Understanding the complex interplay between the promoter domains and the transcription factors may suggest novel methods for therapeutic intervention. ..
  29. APP GENE PROMOTER IN ALZHEIMER'S DISEASE
    Debomoy Lahiri; Fiscal Year: 2002
    ..Understanding the complex interplay between the promoter domains and the transcription factors may suggest novel methods for therapeutic intervention. ..
  30. Mechanisms of Cholinesterase Inhibitors on Beta-amyloid
    Debomoy Lahiri; Fiscal Year: 2003
    ..This property will be further investigated to maximize their potential effects in decreasing amyloid depositions, and which can be utilized to design better drugs for the treatment of AD. ..
  31. HEART IMAGING AGENTS: A STRUCTURAL-MECHANISTIC STUDY
    David Raffel; Fiscal Year: 2008
    ..These imaging studies will help doctors understand how the nerves of the heart are damaged in diseases, and also can be used to study if the nerve damage can be stopped or reversed with new drug therapies. ..
  32. NFAT and MEF-2 Choreograph Bladder Wall Remodeling Following Partial Outlet Obstr
    Stephen Zderic; Fiscal Year: 2009
    ..New therapy to preserve and enhance native bladder function will help avoid the development of the end stage bladder. ..
  33. PERINATAL HYPOXIA: ADRENOCORTICAL-METABOLIC ADAPTATIONS
    Hershel Raff; Fiscal Year: 2006
    ..Characterization of the hypothalamic-pituitary-adrenal and metabolic adaptations to perinatal hypoxia can lead to new diagnostic approaches and therapies to minimize morbidity and mortality. ..
  34. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2004
    ..abstract_text> ..
  35. APP GENE PROMOTER IN ALZHEIMER'S DISEASE
    Debomoy Lahiri; Fiscal Year: 2004
    ..Understanding the complex interplay between the promoter domains and the transcription factors may suggest novel methods for therapeutic intervention. ..
  36. HEART IMAGING AGENTS--STRUCTURAL MECHANISTICS STUDY
    David Raffel; Fiscal Year: 2004
    ..Finally, [11C]- and [18F]-labeled polar derivatives of the psychostimulant methcathinone will be synthesized as potential NET markers and their in vitro NET affinities determined as the cloned human NET transporter. ..
  37. PERINATAL HYPOXIA--ADRENOCORTICAL/METABOLIC ADAPTATIONS
    Hershel Raff; Fiscal Year: 2001
    ..Specific aim 5 will determine if the dramatic changes in plasma lipids which occur in the hypoxic, suckling rat, are a major influence on aldosteroidogenesis. ..
  38. APP GENE PROMOTER IN ALZHEIMER'S DISEASE
    Debomoy Lahiri; Fiscal Year: 2003
    ..Understanding the complex interplay between the promoter domains and the transcription factors may suggest novel methods for therapeutic intervention. ..
  39. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2005
    ..abstract_text> ..
  40. Hsp90 as a Target for the Treatment of Childhood Cancer
    Rochelle Bagatell; Fiscal Year: 2007
    ..Upon completion of the award period, Dr. Bagatell will be well prepared to move forward as an independent investigator. ..
  41. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2003
    ..Further, improved understanding of the mechanisms of unconsciousness should lead to an improved understanding of consciousness. ..
  42. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2006
    ..abstract_text> ..
  43. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2000
    ..Further, improved understanding of the mechanisms of unconsciousness should lead to an improved understanding of consciousness. ..
  44. Molecular Classification of Suspicious Thyroid Tumors
    Martha Zeiger; Fiscal Year: 2009
    ..abstract_text> ..
  45. Regulation of APP Pathway Gene Promoters in Alzheimer's
    Debomoy Lahiri; Fiscal Year: 2005
    ..Studying APP and BACE gene regulation is crucial to understand APP production leading to Aa generation. These studies should help developing suitable drug targets for the treatment of Alzheimer's disease. ..
  46. Mechanisms of Cholinesterase Inhibitors on Beta-amyloid
    Debomoy Lahiri; Fiscal Year: 2005
    ..This property will be further investigated to maximize their potential effects in decreasing amyloid depositions, and which can be utilized to design better drugs for the treatment of AD. ..
  47. Cholinesterase Inhibitors in Alzheimer's Disease
    Debomoy K Lahiri; Fiscal Year: 2010
    ..The outcome of the proposal is to identify mechanisms by which ChEIs block potentially toxic AB levels and to utilize this property in developing novel therapeutic agents. ..
  48. Regulated Retrotransposon Elements in Neuroendocrine System
    Janusz Puc; Fiscal Year: 2007
    ....
  49. Regulation of APP Pathway Gene Promoters in Alzheimer's
    Debomoy Lahiri; Fiscal Year: 2006
    ..Studying APP and BACE gene regulation is crucial to understand APP production leading to Aa generation. These studies should help developing suitable drug targets for the treatment of Alzheimer's disease. ..
  50. Mechanisms of Cholinesterase Inhibitors on Beta-amyloid
    Debomoy Lahiri; Fiscal Year: 2002
    ..This property will be further investigated to maximize their potential effects in decreasing amyloid depositions, and which can be utilized to design better drugs for the treatment of AD. ..
  51. Regulated Retrotransposon Elements in Neuroendocrine System
    Janusz Puc; Fiscal Year: 2008
    ....
  52. Anesthetics and Alzheimer's Disease
    Roderic G Eckenhoff; Fiscal Year: 2010
    ....
  53. IMAGING COX-2 GENE EXPRESSION IN INFLAMMATION AND TUMORS
    Harvey Herschman; Fiscal Year: 2008
    ..Studies with this mouse will correlate optical and microPET imaging technologies. ..
  54. The role of epidermal, fibroblast and endothelial cell COX-2 in skin cancer
    Harvey Herschman; Fiscal Year: 2007
    ..We anticipate we will be able to define the critical cells and times for COX-2 cancer enhancement. ..
  55. Molecular mechanisms of fatty liver disease: role of the protein DBC1
    Eduardo Chini; Fiscal Year: 2009
    ..These alarming data and predictions clearly show that it is imperative to further understand the molecular mechanisms that modulate the development of liver steatosis. ..
  56. IMAGING COX-2 GENE EXPRESSION IN INFLAMMATION AND TUMORS
    Harvey Herschman; Fiscal Year: 2009
    ..Studies with this mouse will correlate optical and microPET imaging technologies. ..
  57. Anesthetics and Alzheimer's Disease
    Roderic Eckenhoff; Fiscal Year: 2009
    ....
  58. NEUROTROPHIC FACTOR AND NEURONAL PRIMARY RESPONSE GENES
    Harvey Herschman; Fiscal Year: 1999
    ..We will use RDA to identify NGF-induced genes necessary for PC12 differentiation, and to identify additional depolarization-specific IEGs. ..
  59. MUTANT P53 GAIN OF FUNCTION IN TUMORIGENESIS
    Gerard Zambetti; Fiscal Year: 2002
    ..The studies proposed here will build on these observations and contribute to our understanding of how mutation of p53 enhances cell growth and tumorigenicity. ..
  60. INFANT APHAKIA TREATMENT STUDY
    Scott Lambert; Fiscal Year: 2004
    ..abstract_text> ..
  61. Computer Aided Liver Lesion Detection Algorithm
    Lawrence Schwartz; Fiscal Year: 2005
    ..Clearly this is the first step in a process of development and if successful will lead to further efforts in automated detection and characterization. ..
  62. HEART IMAGING AGENTS: A STRUCTURAL-MECHANISTIC STUDY
    David Raffel; Fiscal Year: 2006
    ..This systematic study of [11C]guanidines should result in the development of a tracer with optimal kinetics for quantifying cardiac sympathetic nerve density with PET. ..
  63. Detecting Med Errors in Rural Hospitals Using Technology
    C Brown; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  64. IMAGING COX-2 GENE EXPRESSION IN INFLAMMATION AND TUMORS
    Harvey Herschman; Fiscal Year: 2006
    ..Studies with this mouse will correlate optical and microPET imaging technologies. ..
  65. HEART IMAGING AGENTS: A STRUCTURAL-MECHANISTIC STUDY
    David Raffel; Fiscal Year: 2007
    ..This systematic study of [11C]guanidines should result in the development of a tracer with optimal kinetics for quantifying cardiac sympathetic nerve density with PET. ..
  66. Molecular Classification of Suspicious Thyroid Tumors
    Martha Zeiger; Fiscal Year: 2007
    ..abstract_text> ..
  67. NEUROTROPHIC FACTOR AND NEURONAL PRIMARY RESPONSE GENES
    Harvey Herschman; Fiscal Year: 1993
    ....
  68. NEUROTROPHIC FACTOR AND NEURONAL PRIMARY RESPONSE GENES
    Harvey Herschman; Fiscal Year: 1992
    ....
  69. CORRECTION OF MONOCULAR APHAKIA--IOLS
    Scott Lambert; Fiscal Year: 1990
    ..In addition, clinical and behavioral results will be compared with morphological changes in the lateral geniculate nucleus and the striate cortex...
  70. Neurotrophic Factor & Neuronal Primary Responses Genes
    Harvey Herschman; Fiscal Year: 2004
    ..Finally, we will determine mechanisms by which (i) NGF induces UPAR and (ii) UPAR modulates NGF-driven neuron differentiation. ..